Hemab Therapeutics Holdings Inc. (COAG)
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
COAG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.84B
- EPS (TTM)
- -$3.55
- Dividend yield
- None
- 52-week range
- 23.00 – 55.42
- Day range
- 38.77 – 40.19
- Volume / Avg
- 347.01K / 495.96K
- Beta
- —
- Shares outstanding
- 46.73M
52-week range
COAG stock today
Shares of Hemab Therapeutics (COAG) finished lower on Nov 20 at $39.29, a drop of 1.43% or $0.57 per share, versus the S&P 500's 3.70% decline. At this level, COAG sits in the middle of its 52-week range of $23.00 to $55.42: 29.1% below the high, set on Aug 14, 2026 and 70.8% above the low. Hemab Therapeutics has posted a net loss over the last twelve months (EPS of -$3.55), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Hemab Therapeutics
Company profileHemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Benny Sorensen M.D., Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 59
- IPO year
- 2026
- Website
- hemab.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$63.00+60.35%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.58 vs $-0.51
- Surprise
- -13.73%
COAG news
All COAG news- Hemab Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Hemab (COAG) Q3 2026 Earnings Call TranscriptNasdaq
- Why is Hemab Therapeutics stock sliding today?Investing.com
- Hemab Therapeutics Holdings GAAP EPS of -$0.58 misses by $0.06Seeking Alpha
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann ThrombastheniaGlobeNewswire
- Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and ExpositionGlobeNewswire
- Rodman & Renshaw Initiates Coverage of Hemab Therapeutics Holdings with BuyNasdaq
Hemab Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs COAG |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs COAG |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs COAG |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs COAG |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs COAG |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs COAG |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs COAG |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs COAG |
Indexes, lists and sector
Hemab Therapeutics stock FAQ
What is Hemab Therapeutics's stock price today?
COAG last traded at $39.29 as of Nov 20, 4:00 PM EST, down 1.43% on the day. Prices are delayed at least 15 minutes.
Who is Hemab Therapeutics's CEO?
Dr. Benny Sorensen M.D., Ph.D. is the chief executive officer of Hemab Therapeutics Holdings Inc., which has about 59 employees.
What is the COAG 52-week high?
The 52-week high for COAG is $55.42 and the 52-week low is $23.00. The stock is currently 29.1% below its high.